COCH

Envoy Medical Inc Class A Common Stock (COCH) | Rumor.io

Envoy Medical

COCH

Attention (50-day avg)0%

Attention rank (50-day avg)#4,659

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.56

Market capitalization53.4M

Earnings per share-0.76

Dividend yield (TTM)—

Revenue (annual)241K

Net income (annual)-23.8M

Social

What share of all stock conversation is about COCH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 14

COCH has announced positive 12-month data from its pivotal clinical trial, showing continued improvement in speech perception.
The market appears to be rewarding this setup, with some investors suggesting buying dips and selling rips until FDA approval is secured.
The stock has been developing in a healthy way, with some analysts suggesting it's a good one to hold long, particularly with FDA approval on track for early next year.

Generated by AI

Sentiment

Of the messages about COCH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	77.85% +22.82
Bearish	—	—	—	22.15% -22.82

Bullish· Feb 11

The price of COCH has increased from $0.51 to $0.77, with the potential for further growth towards $0.92-$0.94.
The asset has a relatively small float of 14 million shares and high ownership of 58%, which could lead to significant price movements.
COCH has the potential for a significant price increase, with some investors expecting a "MONSTER gain" and comparing its potential to other successful assets like NCI.

Bearish· Oct 8

The company's recent offering has led to a significant drop in price, with some investors exiting the market faster than expected.
The stock has been heavily shorted, with a large number of open short shares that could be difficult to cover if good news comes out.
The stock has broken through a key support level at $1, and is struggling to recover, with some investors expecting a 50% haircut in value.

Generated by AI

Topics

Of the messages about COCH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	0.89%
Technical Analysis	—	—	—	0.29%
Earnings	—	—	—	0%
Analysts	—	—	—	49.66%
Macro	—	—	—	49.15%
Controversies	—	—	—	0.01%

Announcements· Oct 8

Envoy Medical, Inc. (COCH) raised $4 million in a registered direct offering and private placement of stock and warrants at $1.33 per share.
The company announced an up to $16 million registered direct offering priced at-the-market under Nasdaq rules.
Envoy Medical's shares surged 97% after the FDA fast-tracked the approval of its Acclaim cochlear implant, a version of the Esteem implant that has been on the market for over a decade.

Technical Analysis· Oct 7

The technical analysis suggests a potential breakout above $1.7, with a possible target of $2 or higher.
The stock is forming a potential reversal setup after reclaiming ground, with a possible push back toward the $1.95-$2 zone with a VWAP at $0.91.
The stock is showing bullish signs, with a sharp fade off highs but holding the bounce off the 0.618 fib at $1.68, and a possible bull flag formation.

Generated by AI

Community

Of the messages about COCH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	1.18%
Newcomers	—	—	—	98.82%

Oct 8

New investors are considering Envoy Medical, Inc. ($COCH) after it reached a $9.25 price target.
A recent registered direct offering raised $4 million for Envoy Medical, with a 37.1% pre-market price drop.
The stock's price and volume have increased significantly, with a confirmed bull flag pattern and a momentum ripple effect.

Generated by AI

White Bear Lake, Minnesota--(Newsfile Corp. - September 2, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that Brent Lucas, Envoy Medical's Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, on September 14-16, 2026 at the Lotte New York Palace Hotel in New York City.H.C. Wainwright Conference Presentation...

27d agoYahoo Finance

Are Medical Stocks Lagging Compugen (CGEN) This Year?

Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.

1mo agoYahoo Finance

Also Discussed

Investors talking about COCH also mention

#	Name	Attention
1	Ainos, Inc.AIMD	0%+0
2	CleanCore Solutions Inc. Class B Common StockZONE	0%+0
3	Veea Inc.VEEA	0%0
4	Nouveau Monde Graphite Inc.NMG	0%0
5	GCL Global Holdings LtdGCL	0%0
6	Rein Therapeutics Inc.RNTX	0%0
7	REalloys Inc.BLBX	0%0
8	Wrap Technologies Inc.WRAP	0%0
9	Telomir Pharmaceuticals, Inc.TELO	0%0
10	ATA Inc-ChinaATAI	0%new

Envoy Medical Inc Class A Common Stock

Healthcare
Medical Devices

Envoy Medical Inc Class A Common Stock represents ownership in Envoy Medical, a hearing health company focused on medical technologies for people with hearing loss. The company develops and markets fully implanted hearing solutions, with its current product portfolio centered on the Esteem FI-AMEI, a fully implanted active middle ear implant, and related replacement components. Envoy Medical also has an investigational cochlear implant program under development, reflecting its broader role in the hearing device market. Based in White Bear Lake, Minnesota, the company operates in the healthcare and medical devices space and serves patients and providers seeking alternatives to traditional hearing aids and other hearing technologies. Its business is concentrated in the hearing segment, where it aims to improve usability, access, and quality of life through implantable solutions.

Website

Location

4875 White Bear Parkway

White Bear Lake, MN, 55110

United States

Social

What share of all stock conversation is about COCH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 14

COCH has announced positive 12-month data from its pivotal clinical trial, showing continued improvement in speech perception.
The market appears to be rewarding this setup, with some investors suggesting buying dips and selling rips until FDA approval is secured.
The stock has been developing in a healthy way, with some analysts suggesting it's a good one to hold long, particularly with FDA approval on track for early next year.

Generated by AI

Sentiment

Of the messages about COCH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	77.85% +22.82
Bearish	—	—	—	22.15% -22.82

Bullish· Feb 11

The price of COCH has increased from $0.51 to $0.77, with the potential for further growth towards $0.92-$0.94.
The asset has a relatively small float of 14 million shares and high ownership of 58%, which could lead to significant price movements.
COCH has the potential for a significant price increase, with some investors expecting a "MONSTER gain" and comparing its potential to other successful assets like NCI.

Bearish· Oct 8

The company's recent offering has led to a significant drop in price, with some investors exiting the market faster than expected.
The stock has been heavily shorted, with a large number of open short shares that could be difficult to cover if good news comes out.
The stock has broken through a key support level at $1, and is struggling to recover, with some investors expecting a 50% haircut in value.

Generated by AI

Topics

Of the messages about COCH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	0.89%
Technical Analysis	—	—	—	0.29%
Earnings	—	—	—	0%
Analysts	—	—	—	49.66%
Macro	—	—	—	49.15%
Controversies	—	—	—	0.01%

Announcements· Oct 8

Envoy Medical, Inc. (COCH) raised $4 million in a registered direct offering and private placement of stock and warrants at $1.33 per share.
The company announced an up to $16 million registered direct offering priced at-the-market under Nasdaq rules.
Envoy Medical's shares surged 97% after the FDA fast-tracked the approval of its Acclaim cochlear implant, a version of the Esteem implant that has been on the market for over a decade.

Technical Analysis· Oct 7

The technical analysis suggests a potential breakout above $1.7, with a possible target of $2 or higher.
The stock is forming a potential reversal setup after reclaiming ground, with a possible push back toward the $1.95-$2 zone with a VWAP at $0.91.
The stock is showing bullish signs, with a sharp fade off highs but holding the bounce off the 0.618 fib at $1.68, and a possible bull flag formation.

Generated by AI

Community

Of the messages about COCH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	1.18%
Newcomers	—	—	—	98.82%

Oct 8

New investors are considering Envoy Medical, Inc. ($COCH) after it reached a $9.25 price target.
A recent registered direct offering raised $4 million for Envoy Medical, with a 37.1% pre-market price drop.
The stock's price and volume have increased significantly, with a confirmed bull flag pattern and a momentum ripple effect.

Generated by AI

Envoy Medical

Social

Jul 14

Sentiment

Bullish· Feb 11

Bearish· Oct 8

Topics

Announcements· Oct 8

Technical Analysis· Oct 7

Community

Oct 8

News

Envoy Medical receives patents in Canada and Hong Kong

Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th

Are Medical Stocks Lagging Compugen (CGEN) This Year?

H.C. Wainwright cuts Envoy Medical stock price target on share count

Envoy Medical earnings beat, revenue fell short of estimates

Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates

Also Discussed

Envoy Medical Inc Class A Common Stock

Company Information

Location

News

Envoy Medical receives patents in Canada and Hong Kong

Envoy Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14th-16th

Are Medical Stocks Lagging Compugen (CGEN) This Year?

H.C. Wainwright cuts Envoy Medical stock price target on share count

Envoy Medical earnings beat, revenue fell short of estimates

Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates

Also Discussed

Social

Jul 14

Sentiment

Bullish· Feb 11

Bearish· Oct 8

Topics

Announcements· Oct 8

Technical Analysis· Oct 7

Community

Oct 8